BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 26320600)

  • 1. [Occurrence, intratumoral heterogeneity, prognostic and predictive potential of microsatellite instability following surgical resection of primary colorectal carcinomas and corresponding liver metastases].
    Ágoston EI; Baranyai Z; Dede K; Bodoky G; Kulka J; Bursics A; Harsányi L; Szász AM
    Orv Hetil; 2015 Sep; 156(36):1460-71. PubMed ID: 26320600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic factors and analysis of microsatellite instability in resected pulmonary metastases from colorectal carcinoma.
    Melloni G; Doglioni C; Bandiera A; Carretta A; Ciriaco P; Arrigoni G; Zannini P
    Ann Thorac Surg; 2006 Jun; 81(6):2008-13. PubMed ID: 16731121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histological response, pattern of tumor destruction and clinical outcome after neoadjuvant chemotherapy including bevacizumab or cetuximab in patients undergoing liver resection for colorectal liver metastases.
    Stremitzer S; Stift J; Singh J; Starlinger P; Gruenberger B; Tamandl D; Gruenberger T
    Eur J Surg Oncol; 2015 Jul; 41(7):868-74. PubMed ID: 25865557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perioperative chemotherapy with or without bevacizumab in patients with metastatic colorectal cancer undergoing liver resection.
    Constantinidou A; Cunningham D; Shurmahi F; Asghar U; Barbachano Y; Khan A; Mudan S; Rao S; Chau I
    Clin Colorectal Cancer; 2013 Mar; 12(1):15-22. PubMed ID: 23021126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemistry for PMS2 and MSH6 alone can replace a four antibody panel for mismatch repair deficiency screening in colorectal adenocarcinoma.
    Hall G; Clarkson A; Shi A; Langford E; Leung H; Eckstein RP; Gill AJ
    Pathology; 2010; 42(5):409-13. PubMed ID: 20632815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thymidylate synthase and microsatellite instability in colorectal cancer: implications for disease free survival, treatment response and survival with metastases.
    Bendardaf R; Lamlum H; Ristamäki R; Korkeila E; Syrjänen K; Pyrhönen S
    Acta Oncol; 2008; 47(6):1046-53. PubMed ID: 17943475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multimarker panel for circulating tumor cells detection predicts patient outcome and therapy response in metastatic colorectal cancer.
    Barbazán J; Muinelo-Romay L; Vieito M; Candamio S; Díaz-López A; Cano A; Gómez-Tato A; Casares de Cal Mde L; Abal M; López-López R
    Int J Cancer; 2014 Dec; 135(11):2633-43. PubMed ID: 24752533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Impact of Mismatch Repair Protein Testing on Outcome of Early Staged Colorectal Carcinomas.
    Gandhi JS; Goswami M; Sharma A; Tanwar P; Gupta G; Gupta N; Pasricha S; Mehta A; Singh S; Agarwal M; Gupta N
    J Gastrointest Cancer; 2018 Dec; 49(4):406-414. PubMed ID: 28585041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic impact of microsatellite instability in colorectal cancer patients treated with adjuvant FOLFOX.
    Des Guetz G; Lecaille C; Mariani P; Bennamoun M; Uzzan B; Nicolas P; Boisseau A; Sastre X; Cucherousset J; Lagorce C; Schischmanoff PO; Morere JF
    Anticancer Res; 2010 Oct; 30(10):4297-301. PubMed ID: 21036755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathologic and molecular characteristics of synchronous colorectal cancers: heterogeneity of clinical outcome depending on microsatellite instability status of individual tumors.
    Bae JM; Cho NY; Kim TY; Kang GH
    Dis Colon Rectum; 2012 Feb; 55(2):181-90. PubMed ID: 22228162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy.
    Giampieri R; Maccaroni E; Mandolesi A; Del Prete M; Andrikou K; Faloppi L; Bittoni A; Bianconi M; Scarpelli M; Bracci R; Scartozzi M; Cascinu S
    Gastric Cancer; 2017 Jan; 20(1):156-163. PubMed ID: 26796888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors for disease-free survival after preoperative chemotherapy followed by curative resection in patients with colorectal cancer harboring hepatic metastasis: a single-institute, retrospective analysis in Asia.
    Yi JH; Kim H; Jung M; Shin SJ; Choi JS; Choi GH; Baik SH; Min BS; Kim NK; Ahn JB
    Oncology; 2013; 85(5):283-9. PubMed ID: 24217184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathologic features of synchronous colorectal carcinoma: A distinct subset arising from multiple sessile serrated adenomas and associated with high levels of microsatellite instability and favorable prognosis.
    Hu H; Chang DT; Nikiforova MN; Kuan SF; Pai RK
    Am J Surg Pathol; 2013 Nov; 37(11):1660-70. PubMed ID: 23887157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance of different microsatellite marker panels for detection of mismatch repair-deficient colorectal tumors.
    Xicola RM; Llor X; Pons E; Castells A; Alenda C; Piñol V; Andreu M; Castellví-Bel S; Payá A; Jover R; Bessa X; Girós A; Duque JM; Nicolás-Pérez D; Garcia AM; Rigau J; Gassull MA;
    J Natl Cancer Inst; 2007 Feb; 99(3):244-52. PubMed ID: 17284719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microsatellite instability testing and its role in the management of colorectal cancer.
    Kawakami H; Zaanan A; Sinicrope FA
    Curr Treat Options Oncol; 2015 Jul; 16(7):30. PubMed ID: 26031544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
    Asseburg C; Frank M; Köhne CH; Hartmann JT; Griebsch I; Mohr A; Osowski U; Schulten J; Mittendorf T
    Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective analysis of KRAS wild-type patients with metastatic colorectal cancer using cetuximab plus FOLFIRI or FOLFOX4 treatment regimens.
    Huang MY; Chen MJ; Tsai HL; Kuo CH; Ma CJ; Hou MF; Chuang SC; Lin SR; Wang JY
    Genet Mol Res; 2011 Oct; 10(4):3002-12. PubMed ID: 21968808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Colorectal Cancer.
    Singapore Cancer Network (SCAN) Colorectal Cancer Systemic Therapy Workgroup
    Ann Acad Med Singap; 2015 Oct; 44(10):379-87. PubMed ID: 26763055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of chemotherapy-associated liver injury in patients with colorectal cancer liver metastases using indocyanine green clearance testing.
    Krieger PM; Tamandl D; Herberger B; Faybik P; Fleischmann E; Maresch J; Gruenberger T
    Ann Surg Oncol; 2011 Jun; 18(6):1644-50. PubMed ID: 21207168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability.
    Lévi F; Karaboué A; Gorden L; Innominato PF; Saffroy R; Giacchetti S; Hauteville D; Guettier C; Adam R; Bouchahda M
    Cancer Chemother Pharmacol; 2011 Feb; 67(2):339-48. PubMed ID: 20401611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.